Latest On Ono Pharmaceutical Co., Ltd (OPHLF):
About Ono Pharmaceutical Co., Ltd (OPHLF):
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
General
- Name Ono Pharmaceutical Co., Ltd
- Symbol OPHLF
- Type Common Stock
- Exchange OTCGREY
- Currency USD
- Country USA
- Full Time Employees 3,560
- Fiscal Year EndMarch
- Web URLhttp://www.ono.co.jp
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $148.77
- Next Year EPS Estimate $175.05
- Next Quarter EPS Estimate $0.25
- Profit Margin 25%
- Return on Assets 9%
- Return on Equity 12%
- Revenue Per Share $0
- Gross Profit 213.36 billion
- Quarterly Earnings Growth 10.7%
ESG Rating
Highlights
- Market Capitalization 15.18 billion
- PEG Ratio 40586.9
Share Statistics
- Shares Outstanding 514.12 million
- Shares Float 464.86 million
- % Held by Insiders 1792%
- % Held by Institutions 33.81%
Technicals
- Beta 0.48
- 52 Week High $31
- 52 Week Low $18
- 50 Day Moving Average 29.26
- 200 Day Moving Average 28.37
Dividends
- Dividend Date 2018-06-25
- ExDividend Date N/A
- Dividend Yield 0%
Ono Pharmaceutical Co., Ltd (OPHLF) Dividend Calendar:
OPHLF's last dividend payment was made to shareholders on June 25, 2018.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Ono Pharmaceutical Co., Ltd (OPHLF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-12-31 | 2020-12-31 | $N/A | $53.37 | $32.81 | 62.66% |
2020-09-30 | 2020-12-31 | $N/A | $0.52 | $31.40 | -98.35% |
2020-06-30 | 2020-09-30 | $N/A | $0.35 | $35.40 | -99.02% |
2020-03-31 | 2020-06-30 | $N/A | $0.40 | $17.21 | -97.68% |
2019-12-31 | 2020-03-31 | $702.33 million | $0.15 | $29.14 | -99.5% |
2019-09-30 | 2019-12-31 | $694.17 million | $0.35 | $26.29 | -98.67% |
2019-06-30 | 2019-09-30 | $683.25 million | $0.30 | $27.20 | -98.89% |
2019-03-31 | 2019-06-30 | $587.64 million | $0.30 | $18.20 | -98.38% |
2018-12-31 | 2019-03-31 | $719.16 million | $0.15 | $36.20 | -99.59% |
2018-09-30 | 2018-12-31 | $642.12 million | $0.25 | $25.80 | -99.02% |
2018-06-30 | 2018-09-30 | $642.43 million | $0.23 | $27.80 | -99.16% |
2018-03-31 | 2018-06-30 | $578.55 million | $0.27 | $7.80 | -96.57% |
2017-12-31 | 2018-03-31 | $702.37 million | $0.16 | $24.80 | -99.35% |
2017-09-30 | 2017-12-31 | $536.81 million | $0.35 | $15.00 | -97.67% |
2017-06-30 | 2017-09-30 | $542.03 million | $0.16 | $21.30 | -99.24% |
2017-03-31 | 2017-06-30 | $55.95 billion | $0.20 | ||
2016-12-31 | 2017-03-31 | $0.23 | $51.10 | -99.56% | |
2016-09-30 | 2016-12-31 | $0.31 | $21.90 | -98.57% | |
2016-06-30 | 2016-09-30 | $0.18 | $26.60 | -99.34% | |
2016-03-31 | 2016-06-30 | $0.25 | $7.20 | -96.51% | |
2015-12-31 | 2016-03-31 | $0.10 | $5.68 | -98.29% | |
2015-09-30 | 2015-12-31 | $0.11 | $0.00 | ||
2015-06-30 | 2015-09-30 | $0.04 | $0.00 | ||
2015-03-31 | 2015-06-30 | $0.15 | $0.00 | ||
2014-12-31 | 2015-03-31 | -$0.04 | $8.98 | -100.48% | |
2014-09-30 | 2014-12-31 | $0.20 | $1.06 | -81.54% | |
2014-06-30 | 2014-09-30 | $0.01 | $0.00 | ||
2014-03-31 | 2014-06-30 | $0.05 | $6.04 | -99.1% | |
2013-12-31 | 2014-03-31 | $0.04 | $0.00 | ||
2013-09-30 | 2013-12-31 | $0.15 | $0.00 | ||
2013-06-30 | 2013-09-30 | $0.07 | $0.00 | ||
2013-03-31 | 2013-06-30 | $0.12 | $0.00 | ||
2012-12-31 | 2013-03-31 | $0.13 | $0.00 | ||
2012-09-30 | 2012-12-31 | $0.14 | $0.00 | ||
2012-06-30 | 2012-09-30 | $0.06 | $0.00 | ||
2012-03-31 | 2012-06-30 | $0.20 | $0.00 | ||
2011-12-31 | 2012-03-31 | $0.15 | $0.00 | ||
2011-09-30 | 2011-12-31 | $0.23 | $0.00 | ||
2011-06-30 | 2011-09-30 | $0.00 | $0.00 | ||
2011-03-31 | 2011-06-30 | $0.20 | $0.00 | ||
2010-12-31 | 2011-03-31 | $0.12 | $0.00 | ||
2010-09-30 | 2010-12-31 | $0.22 | $0.00 |
Ono Pharmaceutical Co., Ltd (OPHLF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Ono Pharmaceutical Co., Ltd (OPHLF) Chart:
Ono Pharmaceutical Co., Ltd (OPHLF) News:
Below you will find a list of latest news for Ono Pharmaceutical Co., Ltd (OPHLF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Ono Pharmaceutical Co., Ltd (OPHLF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Ono Pharmaceutical Co., Ltd (OPHLF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2016-10-17 | F-6 | Registration of American Depository Receipt shares, not immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000095012716000087/0000950127-16-000087-index.htm |
2017-04-26 | F-6/A | Registration of American Depository Receipt shares, not immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000095012717000017/0000950127-17-000017-index.htm |
2017-05-22 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000095012717000026/0000950127-17-000026-index.htm |
2008-10-31 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000101915508000735/0001019155-08-000735-index.htm |
2014-05-23 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000101915514000206/0001019155-14-000206-index.htm |
2016-05-24 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000101915516000592/0001019155-16-000592-index.htm |
2008-10-10 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000110465908063300/0001104659-08-063300-index.htm |
2009-02-20 | RW | Registration Withdrawal Request | https://www.sec.gov/Archives/edgar/data/940821/000115955409000005/0001159554-09-000005-index.htm |
2015-07-24 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000119380515001248/0001193805-15-001248-index.htm |
2016-03-30 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000119380516002953/0001193805-16-002953-index.htm |
2016-08-25 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000119380516003823/0001193805-16-003823-index.htm |
2017-09-29 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000119380517002942/0001193805-17-002942-index.htm |
2019-11-22 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000119380519001593/0001193805-19-001593-index.htm |
2017-04-26 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/940821/999999999517000962/9999999995-17-000962-index.htm |